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Background: Although some authors have recently investigated the co-occurrence of anxiety and bipolar
disorders, the topic remains insufﬁciently studied. Deﬁning the prevalence and predictors of BD–OCD
comorbidity has important nosological, clinical and therapeutic implications.
Methods: A systematic review and meta-analysis was conducted on the prevalence and predictors of
comorbid BD–OCD. Relevant papers published through March 30th, 2015 were identiﬁed searching the
electronic databases MEDLINE, Embase, PsycINFO and the Cochrane Library.
Results: 46 articles met inclusion criteria. The pooled prevalence of OCD in BD was 17.0% (95% CI 12.7–
22.4%), which was comparable to the results reported by the pooled prevalence of BD in OCD (18.35%,
95% CI 13.2–24.8%). With regard to OCD–BD predictors, a higher mean age predicted a lower prevalence
of OCD in BD patients. Sub group meta-analyses reported higher OCD prevalence rates in BD children and
adolescents (24.2%, compared to 13.5% in adults), in BD-I patients (24.6%, compared to 13.6% in mixed BD
patients), and among population-based studies (22.2%, compared to 13.2% in hospital-based studies).
Limitations: Most studies use retrospective assessment scales with low sensitivity in discriminating
true ego-dystonic obsessions from depressive ruminations that may bias results towards an over-
estimation of obsessive symptom prevalence.
Conclusions: This ﬁrst systematic review and meta-analysis of the prevalence and predictors of co-
morbid BD–OCD conﬁrms that BD–OCD comorbidity is a common condition in psychiatry with children
and adolescents and BD-I patients as the most affected subgroups.
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1.1. Background
Apparent comorbidity between bipolar disorder (BD) and ob-
sessive–compulsive disorder (OCD) is a common condition in
psychiatry and it has important nosological and therapeutic im-
plications (Tonna et al., 2015, Amerio et al., 2014c, 2014a, 2014b).
In our previous systematic review, we founded that 50–75% of OCD
cases are limited to mood episodes in BD (Amerio et al., 2014a). OC
symptoms in comorbid patients appeared more often-and sometimes
exclusively-during depressive episodes, and comorbid BD and OCD
cycled together, with OC symptoms often remitting during manic/
hypomanic episodes. In other words, especially among patients with a
primary diagnosis of BD, themajority of comorbid OCD cases appeared
to be secondary to mood episodes (Amerio et al., 2014a).
However, although some authors have recently investigated the
co-occurrence of anxiety and bipolar disorders, no meta-analysis of
prevalence rates or subgroup analyses were performed (Vazquez et al.,
2014).
Adopting a meta-analytic approach provides the advantage of
pooling data from numerous studies in a logical manner to provide a
more accurate effect size which is closer to the true prevalence than
when individual studies are considered separately (Ioannidis, 2009).
Moreover, from a clinical prospective, it could be important to know
the different rates of BD‐OCD comorbid prevalence in adults and
children/adolescents, in different types of BD, study settings or de-
signs, geographical variations.
The present paper is the ﬁrst systematic review and meta-
analysis of the prevalence and predictors of comorbid BD–OCD.
1.2. Aim of the study
We updated our previous systematic review and performed ameta-analysis of the evidence from the literature to deﬁne the
prevalence and predictors of comorbid BD–OCD.2. Materials and methods
We conducted this review according to the methods re-
commended by the Cochrane Collaboration (Higgins and Green,
2011) and to the Meta-analysis Of Observational Studies in Epi-
demiology (MOOSE) guidelines (Stroup et al., 2000) and docu-
mented the process and results in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (Liberati et al., 2009).
2.1. Information sources and search strategy
Studies were identiﬁed searching the electronic databases MED-
LINE, Embase, PsycINFO and the Cochrane Library. We combined the
search strategy of free text terms and exploded MESH headings for the
topics of bipolar disorder and obsessive–compulsive disorder com-
bined as following: (((((((Bipolar disorder) OR BD) OR Bipolar) OR
Manic depressive disorder) OR Manic depressive) OR Manic)) AND
(((Obsessive–compulsive disorder) OR Obsessive–compulsive) OR
OCD). The strategy was ﬁrst developed in MEDLINE and then adapted
for use in the other databases (Appendix A). Studies published in
English through March 30th, 2015 were included. In addition, further
studies were retrieved from reference listing of relevant articles and
consultation with experts in the ﬁeld.
2.2. Inclusion criteria
2.2.1. Study population and study design
We considered studies that included BD and OCD subjects if
diagnostic criteria used were speciﬁed. Among BD study
Table 1
Studies that met inclusion/exclusion criteria for systematic review.
References Study design Country Study population Sample size Diagnosis assessment Qualitya
Population-based studies
Adam et al. (2012) Cross-sectional study Germany 4181 subjects (age range¼1865): OCD (n¼30) 30 Broad concept of OCD; DIA-X/M-CIDI;
DSM-IV
25/31
Angst et al. (2004) b Prospective cohort
study
Switzerland 591 subjects recruited at age 19/20 and assessed over 20 years: OCD (n¼30) 30 Broad deﬁnition for BD and OCD;
DSM-IV
26/31
Chen and Dilsaver (1995) Cross-sectional study USA Pt. with BD, unipolar disorder or any Axis I disorder other than bipolar or unipolar disorder
(n¼6622, age418): BD (n¼167)
167 DIS; DSM-III 25/31
Faravelli et al. (2004) Cross-sectional study Italy 2500 subjects randomly selected from the lists of 15 GPs: BD (n¼19, age414), OCD (n¼57,
age414)
76 SCID; DSM-IV 24/31
Fineberg et al. (2013)b Prospective cohort
study
Switzerland 591 subjects recruited at age 19/20 and assessed over 30 years: OCD (n¼30) 30 Broad deﬁnition for BD and OCD;
SPIKE; DSM-IV
25/31
Fireman et al. (2001)c Cross-sectional study USA 1.728.480 subjects (age46): adults with OCD (n¼1078) 1078 NS; DSM-IV 24/31
Fireman et al. (2001)c Cross-sectional study USA 1.728.480 subjects (age46): children and adolescents with OCD (n¼198) 198 NS; DSM-IV 24/31
Merikangas et al. (2007) Cross-sectional study USA 9282 subjects recruited (ageZ18): adults with any BD (n¼408). 408 CIDI; SCID; DSM-IV 25/31
Hospital-based studies: adults
Boylan et al. (2004) Prospective cohort
study
Canada BD (n¼138, age range¼16–65) 138 SCID; DSM-IV 22/31
Centorrino et al. (2006) Case control study USA Adults (n¼62) with BD, OCD or BD–OCD 62 NS; DSM-IV 20/31
Cosoff and Hafner (1998) Case control study Australia Subjects with a psychotic disorder (n¼100, mean age: men¼34.8710.0,
women¼34.979.6): BD (n¼20)
20 SCID-P; DSM-III-R 20/31
Craig et al. (2002) Cross-sectional study USA 450 subjects: BD with psychosis (n¼138, mean age range¼15–60) 138 SCID; DSM-III-R 22/31
Dilsaver et al. (2008) Case control study USA 187 Latino pt. enroled consecutively from 2001 to 2003: BD-I (n¼69, mean
age¼34.9711.8)
69 SCID-CV; DSM-IV 20/31
Diniz et al. (2004) Cross-sectional study Brazil OCD (n¼161, mean age¼30710)) 161 SCID; DSM-IV 21/31
Edmonds et al. (1998) Case control study New Zealand BD (n¼55, mean age¼41.6), ﬁrst-degree relatives (n¼67, mean age¼50.3) 122 DIGS; DSM-IV 20/31
Hantouche et al. (2003) Case control study France OCD (n¼628, mean age CYC–OCD¼35712,mean age NC–OCD¼36714) 628 NS; DSM-IV 24/31
Henry et al. (2003) Cross-sectional study France BD (n¼318, mean age¼53.3715.1) 318 DIGS; DSM-IV 23/31
Kemp et al. (2014) Clinical trial USA BD (BD-I or BD-II) (n¼264, age418) 264 SCID; DSM-IV 21/31
Kim et al. (2014) Cross-sectional study South Korea BD-I (n¼174, age418) 174 SCID; DSM-IV 22/31
Koyuncu et al. (2010) Case control study Turkey BD (n¼214, mean age: BD¼34.8710.3, OCD–BD¼36.2715.9) 214 SCID; DSM-IV 20/31
Kruger et al. (1995) Cross-sectional study Germany Major affective disorder (n¼149, mean age¼49712): BD (n¼44) 37 DIS; DSM-III 21/31
Kruger et al. (2000) Case control study Germany BD-I or BD-II (n¼143, mean age¼44) 143 SCID; DSM-III-R 22/31
Magalhaes et al. (2010) Case control study Brazil BD (n¼259, mean age¼41) 259 SCID; DSM-IV 23/31
Maina et al. (2007) Case control study Italy OCD (n¼204, mean age¼34.7712.1) 204 SCID; DSM-IV 21/31
Marazziti et al. (2002) Cross-sectional study Italy OCD (n¼117, mean age¼3079.3) 117 SCID-P; DSM-IV 21/31
McElroy et al. (2001) Case control study USA BD-I or BD-II (n¼288, mean age¼42.8711.3) 288 SCID-P; DSM-IV 23/31
Perugi et al. (1997) Case control study Italy OCD (n¼315, mean age: BD–OCD¼32.8712.2, OCD¼32.5712.6) 345 NS; DSM-III-R 22/31
Perugi et al. (1998) Case control study Italy OCD (n¼135, mean age¼38.4713.3) 135 NS; DSM-III-R 21/31
Perugi et al. (1999) Case control study Italy 269pt. enroled consecutively from 1993 to 1995: OCD (n¼79, mean age¼30.4711.8) 79 SCID-Up-R; DSM-III-R 20/31
Perugi et al. (2002) Case control study Italy OCD-MDE (n¼68, mean age¼34.2712.5); BD-OCD (n¼38, mean age¼35.9712.2) 68 SCID; DSM-IV 20/31
Saunders et al. (2012) Cross-sectional study USA BD, type I or Schizoaffective Disorder, bipolar type (n¼736, mean age¼42712) 736 DIGS; DSM-IV 19/31
Shashidhara et al. (2015) Cross-sectional study India BD-I (n¼396, age418) 396 SCID; DSM-IV 23/31
Simon et al. (2003) Case control study USA 236 subjects: BD (n¼122, mean age¼40.8712.2) 122 SCID; DSM-IV 23/31
Simon et al. (2004) Cross-sectional study USA BD (n¼475, mean age¼41.7712.8) 475 MINI; DSM-IV 23/31
Strakowski et al. (1992) Cross-sectional study USA BD (n¼41, mean age¼40.4711.7) 41 SCID; DSM-III-R 22/31
Strakowski et al. (1998) Cross-sectional study USA BD, manic or mixed with psychosis (n¼77, mean age¼ 2576) 77 SCID-P; DSM-III-R 22/31
Timpano et al. (2012) Case control study USA OCD (n¼605, mean age¼39.2) 605 SCID-P; DSM-IV 20/31
Tukel et al. (2007) Case control study Turkey OCD (n¼128, mean age¼29.3710.8) 128 SCID-CV; DSM-IV 21/31
Zutshi et al. (2006) Case control study India BD in remission (n¼80, mean age¼30.0677.77) 80 SCID-CV; DSM-IV 22/31
Hospital-based studies: children, adolescents
Dilsaver et al. (2006) Case control study USA Latino adolescents (n¼313): BD (n¼115, mean age¼14.671.5) 115 SCID-CV; DSM-IV 18/31
Joshi et al. (2010) Case control study USA OCD (n¼125, age range¼6–17), BD (n¼82, age range¼6–17) 207 K-SADS-E; DSM-III-R 19/31
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A. Amerio et al. / Journal of Affective Disorders 186 (2015) 99–109102populations, studies that only focused on BD-I, BD-II or BD Non
Otherwise Speciﬁed (Angst et al., 2004) were included. Studies
that considered subjects with bipolar and obsessive–compulsive
spectrums were also included if diagnostic criteria used were
speciﬁed (Angst et al., 2004, Adam et al., 2012). Participants of
both sexes older than 6 years of age were considered. Studies
conducted on subjects with physical comorbidities such as lupus
erythematous or Asperger's disorder were excluded as non-re-
presentative of the study population (Bachen et al., 2009, Mu-
kaddes and Fateh, 2010).
Both population-based and hospital-based studies were in-
cluded. Among hospital-based studies, inpatients, day-hospital
and outpatient subjects were included while emergency care re-
cords were excluded as considered non-representative. All ex-
perimental and observational study designs were included apart
from case reports. Narrative and systematic reviews, letters to the
editor and book chapters were excluded.
2.2.2. Outcome measures
Primary outcomes were (i) lifetime prevalence of comorbid
OCD in BD patients and (ii) lifetime prevalence of comorbid BD in
OCD patients. Studies that reported only data about current pre-
valence were excluded (Dell’Osso et al., 2011). Secondary out-
comes were potential predictors of comorbid BD–OCD.
2.2.3. Study selection and data extraction
Identiﬁed studies were independently reviewed for eligibility
by two authors (AA, MT) in a two-step based process; a ﬁrst
screening was performed based on title and abstract while full
texts were retrieved for the second screening. At both stages dis-
agreements by reviewers were resolved by consensus. Data were
extracted by one author (AA) and supervised by a second author
(SNG) using an ad-hoc developed data extraction spreadsheet. The
data extraction spreadsheet was piloted on 10 randomly selected
papers and modiﬁed accordingly.
2.2.4. Quality assessment
The same authors who performed data extraction (AA, SNG)
independently assessed the quality of selected studies using the
checklist developed by Downs and Black both for randomised and
non-randomised studies (Downs and Black, 1998). Disagreements
by reviewers were resolved by consensus. Table 1 shows the
quality assessment total score assigned to each study.
2.3. Meta-analysis
We pooled individual study data using DerSimonian-Laird propor-
tion method (DerSimonian and Laird, 1986) with StatsDirects and
ComprehensiveMeta-Analysiss software (version 3). Due to anticipated
heterogeneity, a random effects meta-analysis was employed. If there
were three or more studies with relevant data, we planned to calculate
subgroup analyses of the prevalence of OCD according to geographical
region, study setting (inpatient versus outpatient/ community), study
sample (adolescents versus adults) and BD classiﬁcation (BD-I versus
BD-II and mixed). We also anticipated on conducting separate pooled
prevalence of BD according to gender and also classiﬁcation of BD itself.
We assessed publication bias with the visual inspection of a funnel plot
(Higgins and Green, 2011) and the Begg (Begg and Mazumdar, 1994)
and Egger (Egger et al., 1997) tests. In addition, for the main prevalence
analysis we conducted a trim and ﬁll adjusted analysis to remove the
most extreme small studies from the positive side of the funnel plot,
recomputing the effect size at each iteration, until the funnel plot is
symmetric about the (new) effect size (Duval and Tweedie, 2000). Fi-
nally, we conducted several meta-regression analyses (if NZ3) to in-
vestigate potential moderators (age, percentage males and study po-
pulation) with Comprehensive Meta-Analysiss (version 3).
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One thousand one hundred ninety-nine potential studies were
identiﬁed from searching the selected databases and listing references
of relevant articles. After removing duplicates, 756 articles were re-
trieved. Studies were screened and selected on the basis of pre-spe-
ciﬁed inclusion and exclusion criteria (Fig. 1). The search identiﬁed 46
articles that were included in the systematic review: 26 articles about
comorbid OCD in BD, 19 articles about comorbid BD in OCD and one
article that explore bidirectional BD–OCD comorbidity.
3.1. Comorbid OCD in BD
3.1.1. Study characteristics
The characteristics of included studies are reported in Table 1.
Thirteen of the twenty-seven studies were cross-sectional studies,
twelve case-control studies, one prospective cohort study and one
clinical trial. Three (11%) studies were population-based while the
majority (N¼24, 89%) was hospital-based. Four studies considered
speciﬁcally child and adolescent populations. In total 4983 BD patients
were represented among the twenty-seven included studies. The
mean age of BD patients was 31.0 (SD 12.2) and 40.3% were males (12–
76.8%). The majority of the studies were conducted in North America
(N¼14, 52%). In all the considered studies diagnosis of BD and OCDFig. 1. Flow diagram owere based on the Diagnostic and Statistical Manual (DSM) criteria
and were established using validated assessment scales. Three studies
considered speciﬁcally BD-I patients.
3.2. Meta-analysis of the pooled prevalence of OCD in BD patients
Four thousand nine hundred eighty-three BD patients were included
in the analysis and the pooled prevalence of OCD was 14.9% (95%
CI¼11.3–18.88, Q¼324 (df¼26)) (Fig. 2a). The funnel plot for the main
analysis appeared asymmetrical (Fig. 2b) and the Begg (Kendall’s
tau¼0.45, P¼0.0009) and Egger tests (Egger: bias¼4.17, P¼0.001) in-
dicated publication bias was present. Given this publication bias, OCD
prevalence was recalculated with the trim and ﬁl method and six stu-
dies were trimmedwith a new prevalence of 17.0% (95% CI, 12.7–22.4%).
3.3. Predictors of the prevalence of OCD in BD patients
Considering data from 18 studies, a higher mean age predicted
a lower prevalence of OCD in BD patients (co-efﬁcient¼0.0358,
95% CI 0.0669 to0.0048, z¼2.26). The percentage of males in
the studies was not related to the prevalence of OCD (co
efﬁcient¼0.0097, 95% CI 0.0191 to 0.0385, z¼0.66). There was a
trend for studies conducted in adults to predict a lower prevalence
of OCD (co efﬁcient¼0.8078, 95% CI 1.7325 to 0.117, z¼1.71).f selected articles.
Fig. 2. (a) Pooled prevalence of OCD in BD patients. (b) Funnel plot for the main analysis.
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Fig. 3. (a) Pooled prevalence of BD in OCD patients. (b) Funnel plot for main analysis.
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3.4.1. OCD prevalence according to the BD type
OCD prevalence among three studies conducted in BD-I pa-
tients was 24.62% (95% CI¼4.86–53.0%, n¼639), while OCD pre-
valence among studies conducted in mixed BD patients (BD-I, BD-
II, BD NOS) was lower at 13.6% (95% CI 10.2–16.8, n¼ 4264,
z¼2.5).3.4.2. OCD prevalence in adult versus adolescent populations
OCD prevalence among studies conducted in adults (N¼22)
was 13.56% (95% CI¼10.4–16.25, n¼4539). The pooled OCD pre-
valence of OCD among studies conducted in children and adoles-
cents (n¼4) was signiﬁcantly higher at 24.2% (95% CI¼10.36–
41.60, n¼345, z¼9.5).
3.4.3. Geographical variations in the prevalence of OCD
The pooled OCD prevalence in BD patients among studies
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n¼ 3213) was higher compared to European (11.7%, 95% CI¼2.4–
26.6, N¼3, n¼498, z¼4.0) and Asian studies (10.6%, 95% CI¼6.8–
14.5, N¼4, n¼705, z¼2.6).
3.4.4. OCD prevalence according to the study setting
Three population-based studies reported a pooled OCD pre-
valence of 22.2% (95% CI 6.1 –44.8%, n¼467) in BD patients. The
prevalence of OCD in BD patients among hospital-based studies
was lower at 13.2% (95% CI 9.9–16.8%, n¼4436, z¼6.7).
3.4.5. OCD prevalence according to study design
Eleven case control studies reported a pooled OCD prevalence
of 13.6% (95% CI 10.1–17.5%, n¼2037) in BD patients. The pre-
valence of OCD in BD patients among cross sectional studies was
12.0% (95% CI 7.4–17.6%, n¼2389, z¼1.9).
3.5. Comorbid BD in OCD
3.5.1. Study characteristics
The characteristics of included studies are reported in Table 1.
Ten of the twenty studies were case-control studies, seven cross-
sectional studies and three prospective cohort studies. Five studies
(25%) were population-based while the majority (N¼15, 75%) was
hospital-based. Five studies considered speciﬁcally child and
adolescent populations. In total 4406 BD patients were re-
presented among the twenty included studies. The mean age of BD
patients was 25.3 (SD 10.18) and 47.5% were males (36.6–69%). The
majority of the studies were conducted in Europe (N¼12, 60%). In
all the considered studies diagnosis of BD and OCD were based on
the Diagnostic and Statistical Manual (DSM) criteria and were
established using validated assessment scales.
3.6. Meta-analysis of the pooled prevalence of BD comorbidity in
OCD patients
Four thousand four hundred six OCD patients were included in
the analysis and the pooled prevalence of BD was 18.47% (95% CI
13.7–23.7, Q¼380) (Fig. 3a). The funnel plot for the main analysis
appeared somewhat asymmetrical (Fig. 3b) and the Begg (0.46,
P¼0.0038) and Egger tests (Egger: bias¼4.4, P¼0.003) indicated
publication bias was present. Given this publication bias, the BD
prevalence was recalculated with the trim and ﬁl method with a
new prevalence of 18.35% (95% CI 13.2–24.8%).
3.7. Predictors of the prevalence of BD in OCD patients
Meta regression analysis demonstrated that mean age (co-ef-
ﬁcient 0.0235, 95% CI 0.0599 to 0.0129, z¼1.27) and mean
percentage of males (co efﬁcient 0.006, 95% CI 0.0308 to 0.0429,
z¼0.32) did not predict the prevalence of BD in the OCD samples.
In addition, no relationship was observed in the meta regression
analysis on the study setting or sample population (adults or
adolescent).
3.8. Sub group meta-analyses
3.8.1. Prevalence of BD in adult versus child and adolescent
populations
BD prevalence in OCD patients (age418) among 15 studies was
19.6% (95% CI 14.4–25.3, n¼3678). Five studies considered speci-
ﬁcally children and adolescents with OCD and BD prevalence was
14.6% (95% CI 4.5–29.1, n¼728).
3.8.2. Geographical variations in the prevalence of BD
The pooled prevalence of BD among OCD patients amongstudies (N¼5) conducted in North America was 14.1% (95% CI 7.5–
22.3%, n¼2046). The pooled prevalence of BD in studies conducted
in Europe (N¼12) was 24.4% (95% CI 17.3–32.2, n¼2017, z¼8.8).
3.8.3. Prevalence of BD according to setting of the study
Fifteen hospital-based studies investigated BD prevalence
among OCD patients with a pooled prevalence of 18.59% (95% CI
13.6–24.1) which was comparable to the results reported by the
ﬁve population-based studies (18.56%, 95% CI 7.8–32.6%).
3.8.4. Prevalence of BD according to study design
The pooled BD prevalence in OCD patients was 20.6% (95% CI
14.5–27.5%, n¼2614) in case-control studies (N¼11), 8.39% (95% CI
4.7–12.9%, n¼1638, z¼8.9) in cross-sectional studies (N¼6), and
37.9% (95% CI 21.3–56.2%, n¼154) in prospective cohort studies
(N¼3).
3.8.5. Prevalence of BD according to different BD type
There were insufﬁcient data to conduct sub group analyses
according to BD classiﬁcation.4. Discussion
Apparent comorbidity between bipolar disorder (BD) and ob-
sessive–compulsive disorder (OCD) is a common condition in
psychiatry. In a classic 1860 text French psychiatrist Bénédict–
Augustin Morel described patients with comorbidity of symptoms
typical of what are now considered BD and OCD (Morel, 1860).
Although recent studies have recently investigated the prevalence
of co-occurrence of anxiety and bipolar disorders (Vazquez et al.,
2014), the topic remains insufﬁciently studied. However, given the
available scientiﬁc evidence, some observations can be made.
The pooled prevalence of OCD in BD was 17.0%, which was
comparable to the results reported by the pooled prevalence of BD
in OCD (18.35%). With regard to OCD–BD predictors, a higher mean
age predicted a lower prevalence of OCD in BD patients. Sub group
meta-analyses reported higher OCD prevalence rates in BD chil-
dren and adolescents (24.2%, compared to 13.5% in adults), and
especially in BD-I patients (24.6%, compared to 13.6% in mixed BD
patients). Higher OCD prevalence rates in BD among population-
based studies (22.2%, compared to 13.2% among hospital-based
studies) could be explain by low sensitivity assessment scales used
to evaluate large sample of people.
Comparing studies conducted in North America and in Europe,
the pooled prevalence of OCD among BD patients was higher in
North America (16.4% vs. 11.7%), while the pooled prevalence of BD
among OCD patients was higher in Europe (24.4% vs. 14.1%).
Geographical variations between BD–OCD comorbidity prevalence
rates could reﬂect different thresholds for BD diagnosis (i.e. cate-
gorical vs. dimensional approach) and a different accuracy in di-
agnosing OCD (i.e. discrimination between true ego-dystonic ob-
sessions and depressive ruminations).
Considering the important nosological, clinical and therapeutic
implications, the entire question of BD–OCD comorbidity deserves
attention, which we have provided separately (Amerio et al.,
2014a, 2014c, 2014b, Tonna et al., 2015).
From a nosological perspective, considering course of illness as
a key diagnostic validator, especially among patients with a pri-
mary diagnosis of BD, the majority of comorbid OCD cases ap-
peared to be secondary to mood episodes (Amerio et al., 2014a).
OC symptoms in comorbid patients appeared more often-and
sometimes exclusively-during depressive episodes, and comorbid
BD and OCD cycled together, with OC symptoms often remitting
during manic/hypomanic episodes (Amerio et al., 2014a). These
results conﬁrm the hypothesis of Mayer-Gross and colleagues
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(BD–OCD patients) who, in time of health, show no noteworthy
obsessional traits, but who have phases in which compulsive symp-
toms appear out of the blue and rapidly mount up to complete in-
capacitation…. Nevertheless these illnesses remit and relapse in very
much the same way as cyclothymic illnesses, may show just as much
regularity of timing, and are probably to be included, from the ae-
tiological point of view, in the manic-depressive disorders” (Mayer-
Gross et al., 1969). On the contrary, especially among patients with
a primary diagnosis of OCD, there is a substantial minority of co-
morbid BD–OCD that may represent “true” OCD independent of BD
with OC symptoms that improve or worsen during mood episodes
without being related to these.
With regard to the clinical meaning, OC symptoms (i) may be
expression of a vulnerability to the development of BD preceding
their clinical onset for many years; (ii) they may have a patho-
plastic inﬂuence, especially in “soft” bipolar spectrum disorders
(cyclothimia); and (iii) they might confer, at a mild level of se-
verity, order and stability to daily life activity, thus compensating
possible functioning decline in BD (Tonna et al., 2015).
Results from our meta-analysis would support the ﬁrst hy-
pothesis with higher comorbidity rates in youths compared to
adults. As conﬁrmed by recent studies, OC symptoms in childhood
and adolescence would increase the risk of a later BD diagnosis
preceding the BD onset (Cederlöf et al., 2014, D’Ambrosio et al.,
2010). We speculate that OC symptoms initially would coexist
with BD symptoms even cycling together and they gradually
would tend to decrease in the adulthood.
From a therapeutic perspective, mood stabilisation should be
the primary goal in treating BD–OCD patients. Beneﬁt with neu-
roleptics was also seen, although a few reports also exist of ex-
acerbation of OC symptoms with neuroleptic agents. Addition of
SRI agents and other antidepressants seemed to be less effective
and more harmful in BD–OCD than in non-comorbid patients.
Nonetheless, in a minority of BD patients with refractory OCD,
addition of low doses of antidepressants might also be considered
while strictly monitoring emerging symptoms of mania and hy-
pomania (Amerio et al., 2014c).
Further original studies are needed to clarify BD–OCD pre-
valence rates, diagnostic validity, clinical meaning and treatment
approach. In particular, assessment scales with high sensitivity in
discriminating true ego-dystonic obsessions from depressive ru-
minations are essential to estimate the real prevalence of ob-
sessive symptoms in these patients.5. Limitations
The main limitation of this systematic review is linked to the
study design and analysis strategy of the included studies, as1
2
3
4
5
6
7
8documented in the quality assessment scale used. Most studies are
observational and based on retrospective assessments. The use of
retrospective assessment scales with low sensitivity in dis-
criminating true ego-dystonic obsessions from depressive rumi-
nations may have biased results towards an overestimation of
obsessive symptom prevalence. Some of them do not include a
control group. Small sample size and enrolment of subjects mainly
from BD–OCD outpatient units may limit generalisability of these
results. Potential confounding factors in these studies include
demographic and historical illness variables, which often were not
appropriately analysed through multivariate modelling.
The strength of the selected studies is that the diagnosis of BD
and OCD were consistently based on the DSM criteria and were
established by trained investigators using validated assessment
scales mainly with interrater reliability. The main strength of this
review is its being systematic and its including the entire scientiﬁc
evidence published so far on the main medical databases.Fundings
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